• Facebook
  • Rss
  • Twitter
  • Youtube
  • Store
  • Donate
NCCS - National Coalition for Cancer Survivorship
  • About
    • Our Mission
    • Our History
    • Our Leadership
      • Policy Advisors
    • Employment
    • Partnerships
    • Financial Information
  • Policy
    • Quality Cancer Care
    • Access to Care
    • Health Equity
    • Redefining Functional Status (RFS)
    • 2020 State of Cancer Survivorship Survey
    • Cancer Care Planning and Communications Act (CCPCA)
  • Get Involved
    • What is Advocacy?
    • Cancer Policy and Advocacy Team (CPAT)
    • Elevating Survivorship
    • Survivor Stories
    • Cancerversary
    • State Based Cancer Advocacy
  • Resources
    • COVID-19 Resources for Cancer Survivors
    • Survivorship Checklist
    • Cancer Survival Toolbox
    • Telehealth
    • Survivorship Champions
    • Publications
      • Talking With Your Doctor
      • Self Advocacy
      • Employment Rights
      • Remaining Hopeful
    • Cancer Convos Podcast
    • Taking Charge of Your Care
    • Care Planning for Cancer Survivors
    • Tools For Care Providers
    • Order Our Resources
  • News
  • Events
    • Ellen L. Stovall Award
      • Nominations
      • Honorees
      • Sponsors
      • Committees
    • From Shadows to Life: A Biography of the Cancer Survivorship Movement
    • Cancer Policy Roundtable
      • Spring 2021 Cancer Policy Roundtable
      • Fall 2020 Cancer Policy Roundtable
      • Spring 2020 Cancer Policy Roundtable
    • Cancer Policy and Advocacy Team (CPAT) Symposium 2020
    • Webinars
  • Contact Us
  • Search
  • Menu Menu
  • 0Shopping Cart

Year-End MATCH (DEADLINE Dec 31): Donate & Make a Difference | Donate

NCCS Policy Comments FDA bldg

NCCS Joins Cancer Leadership Council Recommendations to FDA Regarding the Biosimilar Action Plan

September 26, 2018/in Cancer News, Cancer Policy Blog, FDA, NCCS News, Policy Comments Financial Toxicity, Health Equity NCCS News, Policy Comments /by actualize
FDA Building
NCCS joined with other organizations of the Cancer Leadership Council (CLC) in commenting on the Food and Drug Administration’s (FDA) Biosimilar Action Plan (BAP). The comment letter commended the FDA for the development of a plan that balances both innovation and competition. The letter stated that these products provide significant benefits to cancer patients, but that they also come at a significant expense to patients and the health care system.

In the letter, the groups explained that patient-centered communication efforts around education on biosimilars are important, and recommended product-specific efforts that will inform patient decision-making, including whether a product is a biosimilar or also an interchangeable product. The letter states, “Information about biosimilars that is accessible to the patient will support informed decision-making and long-term management of cancer and treatment side effects.”

Read the full CLC Letter below.

Download the CLC Letter


CANCER LEADERSHIP COUNCIL

A PATIENT-CENTERED FORUM OF NATIONAL ADVOCACY ORGANIZATIONS
ADDRESSING PUBLIC POLICY ISSUES IN CANCER

September 21, 2018

Scott Gottlieb, MD
Commissioner
Food and Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993-0002

Re: FDA-2018-N-2689, Facilitating Competition and Innovation in the Biologicals Products Marketplace; Request for Comments

Dear Dr. Gottlieb:

The undersigned cancer organizations are writing to comment on the Biosimilars Action Plan: Balancing Innovation and Competition and the proceedings of the public meeting on biosimilars held on September 4, 2018. We appreciate the opportunity to comment.

We commend the Food and Drug Administration (FDA) for the development of the Biosimilar Action Plan (BAP) articulating a strategy balancing innovation and competition. Biological products have provided significant benefits to cancer patients and are critical elements of cancer care for patients with a wide range of cancer diagnoses. As FDA noted in the BAP, these products have also come at significant expense to the health care system and to individual patients. Protecting access to the benefits of biological products and addressing the cost of these products to patients are important goals of the BAP and goals that, if realized, will benefit patients.

One of the four goals of the action plan is “developing effective communications to improve understanding of biosimilars among patients, clinicians, and payors.” The action plan identifies deliverables related to this communications goal, including: 1) a Biosimilar Education and Outreach Campaign, including an updated FDA Biosimilars website; 2) a webinar providing an overview of the regulatory framework for approval of biosimilars; and 3) a Reddit Ask me Anything (AMA) forum to engage pharmacists on biosimilars. These initial efforts are solid, but we recommend that FDA turn its attention to communications efforts that will directly reach patients and their care teams.

The cancer organizations below are dedicated to a system of cancer care that supports informed decision-making about cancer treatment and includes access to adequate and accurate information supporting patient-centered treatment decisions. For some patients, adequate data and appropriate diagnostic testing support the choice and delivery of targeted therapies. For others, information about their treatment regimen is critical to developing a plan for managing cancer as a chronic disease, including appropriate symptom management. Information about biosimilars that is accessible to the patient will support informed decision-making and long-term management of cancer and treatment side effects.

We note that biosimilar communications efforts to date have focused on overall understanding of biosimilars and their regulatory review. These are important efforts, but we recommend product-specific efforts that will inform patient decision-making. Such educational materials might address whether a product is a biosimilar or also an interchangeable product.

The issue of patient education about biosimilars was one of many areas of focus during the September 4, 2018, meeting. FDA officials asked some patients and patient advocates if information about biological reference products is also necessary for patients, if information about the approval of biosimilars is, in the eyes of patient advocates, critical to patients. In days after the meeting, trade press publications have reported that FDA officials have recommended that the agency produce patient educational materials about the analytical studies that are used to support biosimilar approvals. At the same time, those officials have suggested that patients may not be able to interpret materials about analytics.

We agree that the development of patient-centered materials that would include information about the analytical basis for biosimilar approvals will not be an easy task. We also agree that use of these materials by patients will be a challenge, but we anticipate that these materials would be utilized by patients with their cancer care team and that this collaborative approach would increase the usefulness of the materials. Despite the obstacles, we think that the effort deserves the attention of the agency, and we stand ready to bring our expertise in development of patient materials to a collaboration with the agency. This task is worth our attention and effort because it holds the promise of reassuring patients and the patient community about biosimilars and also providing information to inform treatment decision-making, as we describe above.

There has also been some suggestion that biosimilars should be the subject of post-marketing studies. We suggest that FDA evaluate whether biological reference products and biosimilars might be the subject of real world evidence data collection. Perhaps employing real world evidence efforts in connection with biological reference products and biosimilars used in cancer treatment would be a first step and pilot project for the concept. We understand this is not a simple matter. However, the effort might yield important information for patients, providers, product developers, and the agency.

We appreciate the opportunity to comment on the BAP and look forward to collaborating with the agency on patient education materials.

Sincerely,

Cancer Leadership Council
American Society of Clinical Oncology
CancerCare
Children’s Cause for Cancer Advocacy
Fight Colorectal Cancer
Hematology/Oncology Pharmacy Association
International Myeloma Foundation
The Leukemia & Lymphoma Society
LIVESTRONG
Lymphoma Research Foundation
National Coalition for Cancer Survivorship
Ovarian Cancer Research Fund Alliance
Prevent Cancer Foundation
Sarcoma Foundation of America
Susan G. Komen


Read more NCCS Policy Comments »

Related Posts

https://canceradvocacy.org/blog/nccs-joins-clc-letter-hhs-drug-pricing-blueprint-american-patients-first/

https://canceradvocacy.org/policy-comments/nccs-statement-hhs-final-rule-short-term-health-plans/

Tags: biosimilars, drug approvals, FDA, financial issues, policy comments
Share this entry
  • Share on Facebook
  • Share on Twitter
https://canceradvocacy.org/wp-content/uploads/2018/10/NCCS-Policy-Comments-FDA-bldg.jpg 600 1200 actualize https://canceradvocacy.org/wp-content/uploads/2020/06/NCCA-Logo.png actualize2018-09-26 13:26:122020-07-06 10:05:29NCCS Joins Cancer Leadership Council Recommendations to FDA Regarding the Biosimilar Action Plan
You might also like
Patient Assistance Programs Patient Assistance Programs: Do They Help or Hurt?
dome NCCS Responds to 21st Century Cures Initiative Call to Action
CDC NCCS Urges CDC Committee to Include Cancer Survivors in High-Risk Category for COVID-19 Vaccine Distribution
NCCS Starburst 250px Health Care Roundup: New Health Care Bills; NCCS Co-Founder Susie Leigh on Life After Cancer; Oncology Care Model; Racial Disparities; More
Dome Thumbnail starburst NCCS endorses the Carolyn Pryce Conquer Childhood Cancer Reauthorization Act
FacebookProfile3 NCCS applauds establishment of cancer treatment planning and care coordination reimbursement codes
Dome Thumbnail starburst NCCS Comments on Quality Measures for PPS-Exempt Cancer Hospitals
NCCS Starburst 250px What Caught Our Eye: High-Risk Pools, “Trumpcare,” Childhood Cancer Survivors, Medicaid Spending, Trump’s FDA Deregulation

Latest News

NCCS Founders at 1990 Assembly

The Birth of the Cancer Survivorship Movement and How It Transformed Cancer Care for Millions

March 25, 2021
Guest Post by Judith L. Pearson Best-Selling Author of From Shadows to Life: A Biography…
Read more
https://canceradvocacy.org/wp-content/uploads/2018/02/10-Founders-1990-NCCS-Assembly.jpg 600 1200 NCCS Staff https://canceradvocacy.org/wp-content/uploads/2020/06/NCCA-Logo.png NCCS Staff2021-03-25 10:36:202021-03-25 13:46:05The Birth of the Cancer Survivorship Movement and How It Transformed Cancer Care for Millions
HHS Humphrey bldg 1200

Biden Rescinds Trump Admin Proposal to Limit Medicare Part D Coverage of Drugs in “Six Protected Classes”

March 19, 2021
This week, the Biden administration rescinded a Trump administration-proposed plan…
Read more
https://canceradvocacy.org/wp-content/uploads/2017/10/HHS-Humphrey-bldg-1200.jpg 600 1200 NCCS Staff https://canceradvocacy.org/wp-content/uploads/2020/06/NCCA-Logo.png NCCS Staff2021-03-19 13:36:192021-03-23 14:46:18Biden Rescinds Trump Admin Proposal to Limit Medicare Part D Coverage of Drugs in “Six Protected Classes”
CDC Headquarters

NCCS Recommends That States Allocate COVID-19 Vaccines to Cancer Care Providers

March 1, 2021
The National Coalition for Cancer Survivorship (NCCS) and the Cancer Leadership Council…
Read more
https://canceradvocacy.org/wp-content/uploads/CDC_Headquarters_PHIL_pubdomain_1200.jpg 600 1200 NCCS Staff https://canceradvocacy.org/wp-content/uploads/2020/06/NCCA-Logo.png NCCS Staff2021-03-01 15:49:432021-03-04 17:45:07NCCS Recommends That States Allocate COVID-19 Vaccines to Cancer Care Providers

Take Action

Stovall Award

The Ellen L. Stovall Award for Innovation in Patient-Centered Cancer Care is a unique opportunity for patients and survivors to recognize pioneers who are transforming the cancer care system.

Join CPAT

The NCCS Cancer Policy & Advocacy Team (CPAT) is a program for survivors and caregivers to learn about pressing policy issues that affect quality cancer care in order to be engaged as advocates in public policy around the needs of cancer survivors.

Share Your Story

NCCS represents the millions of Americans who share a common experience – the survivorship experience – living with, through and beyond a cancer diagnosis.

STAY CONNECTED

Together we can improve cancer care for survivors! Sign up to be the first to know about cancer policy issues and ways to take action

  • About
    • Our Mission
    • Our History
    • Our Leadership
      • Policy Advisors
    • Employment
    • Partnerships
    • Financial Information
  • Policy
    • Quality Cancer Care
    • Access to Care
    • Health Equity
    • Redefining Functional Status (RFS)
    • 2020 State of Cancer Survivorship Survey
    • Cancer Care Planning and Communications Act (CCPCA)
  • Get Involved
    • What is Advocacy?
    • Cancer Policy and Advocacy Team (CPAT)
    • Elevating Survivorship
    • Survivor Stories
    • Cancerversary
    • State Based Cancer Advocacy
  • Resources
    • COVID-19 Resources for Cancer Survivors
    • Survivorship Checklist
    • Cancer Survival Toolbox
    • Telehealth
    • Survivorship Champions
    • Publications
      • Talking With Your Doctor
      • Self Advocacy
      • Employment Rights
      • Remaining Hopeful
    • Cancer Convos Podcast
    • Taking Charge of Your Care
    • Care Planning for Cancer Survivors
    • Tools For Care Providers
    • Order Our Resources
  • News
  • Events
    • Ellen L. Stovall Award
      • Nominations
      • Honorees
      • Sponsors
      • Committees
    • From Shadows to Life: A Biography of the Cancer Survivorship Movement
    • Cancer Policy Roundtable
      • Spring 2021 Cancer Policy Roundtable
      • Fall 2020 Cancer Policy Roundtable
      • Spring 2020 Cancer Policy Roundtable
    • Cancer Policy and Advocacy Team (CPAT) Symposium 2020
    • Webinars
  • Contact Us

National Coalition for Cancer Survivorship
8455 Colesville Road  |  Suite 930  |  Silver Spring, MD 20910
877-NCCS-YES  |  info@canceradvocacy.org
Privacy Policy  |  Terms and Conditions

Copyright © 1995-2021 by the National Coalition for Cancer Survivorship
National Coalition for Cancer Survivorship, NCCS, Cancer Survival Toolbox, and related Logos are registered in the United States as trademarks of the National Coalition for Cancer Survivorship.

Health Care Roundup: ‘Misleading’ Pre-Existing Conditions Bill;... NCCS Starburst 250px NCCS Policy Comments HHS bldg NCCS Submits Recommendations to CMS Regarding Proposed Changes to Hospital Outpatient...
Scroll to top

Harmar Brereton, MD

Founder
Northeast Regional Cancer Institute

 

“Perhaps one of the most impactful collaborations in Dr. Brereton’s extraordinary career remains his early work and long friendship with Ellen Stovall. Through him, and in turn through the thousands of lives he has touched, Ellen’s work continues, and her mission lives on.”

—Karen M. Saunders
President, Northeast Regional Cancer Institute